Anupam Rasayan India LimitedQ1 FY27 Results & Financial Update
Anupam Rasayan India Limited: Q1 FY27 consolidated results and company financials – revenue ₹654.98 Cr, PAT ₹51.22 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Anupam Rasayan India price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Anupam Rasayan India Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Anupam Rasayan India Limited reported a consolidated total income of Rs 6,675 million for the first quarter of fiscal year 2027, representing a year-on-year growth of 36% compared to Rs 4,907 million in Q1 FY26, driven by new product commercialization and steady demand across segments.
Consolidated EBITDA for the quarter reached Rs 1,749 million, posting a 35% year-on-year increase from Rs 1,292 million in the corresponding period of the previous year, maintaining an EBITDA margin of 26% supported by a continued focus on high-value products.
Consolidated profit after tax for Q1 FY27 came in at Rs 512 million, registering a 6% year-on-year rise over Rs 485 million reported in Q1 FY26, while standalone total income stood at Rs 3,349 million with a PAT of Rs 320 million.
During the quarter, the company achieved a significant technological milestone by becoming the first entity globally to commercialize Ethyl Trifluoroacetate (ETFA) using flow chemistry, thereby strengthening its capabilities in complex fluorination.
The business expanded its product portfolio by introducing three new commercialized products during Q1 FY27, including one pharmaceutical intermediate for a new drug and two performance material monomers used for reinforced polymers and high-performance engineering fluids.
Strategic growth initiatives progressed across international markets, notably the ongoing integration of newly acquired Jayhawk Fine Chemicals and the planned acquisition of Bliss GVS Pharma to fortify the pharmaceutical and finished formulations platform.
Revenue visibility was further reinforced through a new long-term Letter of Intent signed with BASQUEVOLT, S.A., creating a potential revenue opportunity of up to US$300 million over a 10-year period with expected commercialization in FY27.
01 · Business model
What does Anupam Rasayan India do?
Anupam Rasayan India Limited operates as a fast-growing specialty chemical manufacturer with a core focus on custom synthesis, custom development, and manufacturing of complex molecules for multinational corporations.
The company's revenue engines span life science-related specialty chemicals including agrochemicals, personal care intermediates, and pharmaceutical intermediates, alongside performance materials and fluorinated derivatives.
Through inorganic expansion, the group includes Tanfac Industries Limited as a subsidiary focused on fluorochemicals and backward integration, and Jayhawk Fine Chemicals Corporation as a wholly-owned U.S. subsidiary providing advanced CDMO capabilities and performance materials.
The manufacturing footprint encompasses multiple state-of-the-art facilities located in Sachin and Jhagadia in Gujarat, Cuddalore in Tamil Nadu, and Kansas in the United States, supported by dedicated research and development centers.
02 · Historical context
What shaped the business before this quarter
Acquired a controlling stake in Tanfac Industries Limited in May 2022 to establish backward integration into fluorochemicals and secure uninterrupted access to key raw materials such as hydrofluoric acid and potassium fluoride.
Raised Rs 5,000 million through a Qualified Institutional Placement (QIP) and commissioned a solar power plant of 5.4 MW at Bharuch.
Successfully completed the acquisition of U.S.-based Jayhawk Fine Chemicals Corporation, adding a manufacturing facility in Kansas and expanding global CDMO capabilities into performance materials.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹654.98 Cr |
| Total income | ₹667.55 Cr |
| Profit before tax | ₹69.68 Cr |
| Profit after tax | ₹51.22 Cr |
| EPS | ₹3.39 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Topline expansion was propelled by the successful commercialization of three new products during Q1 FY27, taking the total active product count past 125 complex molecules.
Life science-related specialty chemicals accounted for 41% of consolidated revenue, performance materials contributed 31%, and other fluorinated products through Tanfac generated 28%.
Exports and international operations accounted for 36% of consolidated revenue in Q1 FY27, backed by a global customer base spanning over 14 countries.
What drove margins
Consolidated EBITDA margin held steady at 26% year-on-year for Q1 FY27, supported by an increasing contribution from high-value performance materials and specialized polymer chemistries.
Cost of materials consumed for the quarter stood at Rs 2,847 million on a consolidated basis, reflecting controlled raw material pressures via backward integration through Tanfac.
Consolidated employee expenses were reported at Rs 649 million and other expenses at Rs 1,430 million, while depreciation increased to Rs 561 million following recent capacity additions and asset integration.
05 · Demand, customers & order book
Where demand is coming from
Signed an LoI with BASQUEVOLT, S.A. during Q1 FY27 representing a potential revenue opportunity of approximately US$300 million (Rs 2,850 crores) over a 10-year period, with commercialization slated for FY27.
Cumulative multi-year LOI and contract order book stands at Rs 17,496 crores across multiple global multinational innovators.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Added one new intermediate for a new drug to the portfolio during Q1 FY27, expanding opportunities in key starting materials and advanced pharma intermediates.
Added two new products functioning as monomers for new reinforced polyesters and high-performance engineering fluids, strengthening capabilities in advanced industrial applications.
Geography and market mix
Maintains an active export presence across more than 14 countries, supported by five international sales offices located in Japan, Switzerland, the USA, and the UAE alongside India.
Integration of Jayhawk Fine Chemicals in Kansas provides a strategic U.S. manufacturing platform with approximately 800 acres of land offering substantial expansion headroom.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
Total consolidated manufacturing capacity across eight plants—comprising facilities in Sachin and Jhagadia (Gujarat), Cuddalore (Tamil Nadu), and Kansas (USA)—reached 200,552 MT.
Projects, capex and execution
Capital expenditure and facility investments remain focused on expanding downstream capabilities and scaling utilization across newly integrated platforms in India and the United States.
08 · Strategy & new businesses
How the company is trying to change its growth mix
The proposed acquisition of a 43.3% to 48.2% stake plus an open offer in Bliss GVS Pharma progresses as planned following definitive agreement signoffs, aimed at strengthening the finished formulations and regulated market CDMO platform.
Leveraging advanced process technologies including continuous flow chemistry and photochemistry to synthesize complex molecules with improved safety, better yields, and reduced environmental footprints.
09 · Reported developments
What changed operationally
Consolidated total income grew 36% year-on-year to Rs 6,675 million, accompanied by a 35% increase in EBITDA to Rs 1,749 million for Q1 FY27.
10 · Cash flow & balance sheet
Profit is one thing. Cash and funding tell another part of the story.
Capital allocation & funding
The transaction structure for the proposed Bliss GVS Pharma acquisition incorporates a term loan of approximately Rs 300 crores alongside non-controlling non-voting equity instruments of approximately Rs 1,300 crores.
11 · Management guidance & targets
What management is targeting from here
Management expects multiple pipeline projects and recently signed multi-year LOIs, including contracts with BASQUEVOLT and Elementium, to commence commercial production during FY27.
12 · Beyond the numbers
What changed beyond the numbers
Reported update
ESG Commitments
The company remains on track to achieve energy net zero by 2028 on Scope 1 and Scope 2 emissions and target best-in-class ESG standards.
13 · Key Q&A
The quarter, answered directly
What does Anupam Rasayan India do?
Anupam Rasayan India Limited operates as a fast-growing specialty chemical manufacturer with a core focus on custom synthesis, custom development, and manufacturing of complex molecules for multinational corporations.
What is the clearest takeaway from Q1 FY27?
Anupam Rasayan India Limited reported a consolidated total income of Rs 6,675 million for the first quarter of fiscal year 2027, representing a year-on-year growth of 36% compared to Rs 4,907 million in Q1 FY26, driven by new product commercialization and steady demand across segments.
What drove revenue or demand?
Topline expansion was propelled by the successful commercialization of three new products during Q1 FY27, taking the total active product count past 125 complex molecules.
What mattered most for margins or profitability?
Consolidated EBITDA margin held steady at 26% year-on-year for Q1 FY27, supported by an increasing contribution from high-value performance materials and specialized polymer chemistries.
What changed operationally beyond the headline numbers?
Total consolidated manufacturing capacity across eight plants—comprising facilities in Sachin and Jhagadia (Gujarat), Cuddalore (Tamil Nadu), and Kansas (USA)—reached 200,552 MT.
What is management guiding or targeting from here?
Management expects multiple pipeline projects and recently signed multi-year LOIs, including contracts with BASQUEVOLT and Elementium, to commence commercial production during FY27.
14 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
15 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Bliss GVS Pharma Acquisition Progress: Monitor regulatory approvals and completion milestones for the acquisition of Bliss GVS Pharma and its integration into the consolidated group.
- 02
FY27 Commercialization Execution: Track the scheduled commercialization of new product lines including the BASQUEVOLT supply contract during FY27.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.